Akebia Therapeutics Obtains $1,500,000 New Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2d96a712-0235-4a16-8bdd-ff9ebd9343dd - Date
7/3/2014 - Company Name
Akebia Therapeutics - Mailing Address
245 First Street Cambridge, MA 02142 USA - Company Description
Akebia Therapeutics (NASDAQ: AKBA) is a pharmaceutical company with a focus on treatments for ischemia and improvement of vascular disease. - Website
http://www.akebia.com - Transaction Type
Venture Equity - Transaction Amount
$1,500,000 - Transaction Round
Undisclosed - Proceeds Purposes
The company intends to use the capital to fund clinical development of HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD. - M&A Terms
- Venture Investor
- Venture Investor
